Drug companies face new EU safety notification and referral rules
This article was originally published in SRA
Executive Summary
Drug companies withdrawing medicines from the market for safety or other product-related reasons in the EU must now notify such action to the authorities, and state why they are doing so, under new amendments to the pharmacovigilance legislation1.